INK4 tumor suppressor gene expression in colon cancer cells is repressed by methylation at the CpG island of promoter, but in vivo silencing of p16 gene is not fully understood. Some studies showed that primary colorectal cancer (CRC) tissues often overexpress the p16 protein, while others showed the high incidence of p16 methylation. The aim of this study was to clarify p16 gene regulation in vivo. We used real-time methylationspecific PCR (MSP) to examine density of p16 methylation, and immunohistochemistry, Western blot analysis to determine p16 protein expression. Methylation was detected in 5 CRC cell lines tested and 9 of 21 (42.9%) CRCs. Four of 5 CRC cell lines did not express p16 mRNA, but 6 of 9 CRCs did express p16 mRNA even with methylation. Real-time MSP showed that CRC tissues had a wide variety in methylation density (methylation index: 0.28-0.91) and that highly methylated CRC tissues displayed significantly lower p16 mRNA expression than those with no-methylation or lowmethylation. Immunohistochemistry showed that the majority of CRCs (53 of 55: 96.4%) overexpressed the p16 protein. Low p16 expression was associated with lymph node metastasis (p=0.003) and large tumor size (p=0.048). Western blot in a subset of non-tumor and tumor samples showed a consistent overexpression of the p16 protein. These results showed that CRC tissues displayed variable methylation density, which may be characteristics of p16 gene methylation in vivo. Our data suggest that a low p16 expression due to methylation may contribute to tumor enlargement and expansion of CRC.
Introduction
The progression of the cell cycle is controlled by the cyclindependent kinase (CDK)/cyclin complex countered by CDK inhibitors (CKIs) (1, 2) . Cyclin D1/CDK4, CDK6 and cyclin E/CDK2 control the progression from the G1 to S phase of the cell cycle. Based on their structural and functional characteristics, CKIs are classified into two groups, the p21 Waf1 family, which includes p27 Kip1 and p57 Kip2 , and another group, which consists of p16 INK4a (hereafter designated p16), p15 INK4b , p18 INK4c and p19 INK4d . The p16 gene is localized on chromosome 9p21 and the p16 family can form complexes with CDK4, CDK6 and D-type cyclins (3) (4) (5) . Overexpression of INK4 proteins can arrest cells in the G1 phase through inhibition of cyclin D/CDK activity (6) . On the other hand, p16-deficient mice develop spontaneous tumors at an early stage and are highly sensitive to carcinogens, suggesting that p16 is a tumor suppressor gene (7) . Indeed, deletions and mutations of the p16 gene are frequently present in primary cancers of the brain, biliary tract, lung, pancreas and esophagus (8) (9) (10) (11) (12) , although a panel of cancer cell lines tends to retain p16 gene alterations more frequently (3) . There is also evidence that p16 expression is down-regulated by de novo methylation of 5' CpG islands in the p16 promoter region (13, 14) .
In colorectal cancer (CRC) cell lines, expression of the p16 protein was reported to be undetectable and inactivation of p16 is thought to be a common alteration in CRC (15) . It appears that deletion or loss of the p16 gene is rare in CRC (13, 16, 17) and the alternative pathway for inactivation of the p16 gene is thought to be methylation of its promoter (13, 14) . In CRC tissues, there is evidence that the p16 gene promoter is methylated in 29-55% of primary cancer tissues (13, (18) (19) (20) (21) (22) , whereas in non-neoplastic colonic mucosa the p16 promoter is hardly methylated (18, 23) . These findings invoke the notion that p16 gene inactivation via methylation may be involved in carcinogenesis of the colorectum.
However, recent immunohistochemical studies have shown that the majority of CRC tissues (64-82%) expressed the p16 protein, while normal mucosa displayed negative or very low expression (24, 25) . This overexpression of p16 in CRC tissues is somewhat paradoxical in view of the possible role of p16 as a tumor suppressor gene, indicating that the above scenario on human CRC tumorigenesis via p16 inactivation may not be quite as simple in vivo. The question then arises as to how methylation and overexpression of the p16 gene can coexist in a significant fraction of CRC tissues? One clue to this puzzle might be the difference in methylation density of the CpG island in the p16 promoter between cell culture systems and primary CRC tissues, since it is reported that the level of transcriptional repression is dependent on methylation density (26, 27) . Although many studies have examined the incidence of p16 methylation alone or p16 expression alone in vivo (18) (19) (20) (21) (22) (23) , no study has yet simultaneously examined the degree of methylation and p16 gene expression in CRC tissues. To address this question, we examined p16 methylation and p16 gene expression in CRC tissue samples together with control experiments using CRC cell lines. Real-time methylationspecific PCR (MSP) was also performed in methylationpositive CRC tissue samples. An extended immunohistochemical analysis was conducted to elucidate the functional significance of the p16 protein in CRC tissues. Our data provide a rationale for methylation-associated regulation of p16 expression in primary CRC tissues.
Materials and methods
Cell lines and tissues. The human breast epithelial cell line HBL100, human CRC cell lines HCT116, SW480, LoVo, HT29, DLD1, human breast cancer cell line MDAMB468, and human glioblastoma cell line T98G were obtained from the Japanese Cancer Research Resources Bank and ATCC (American Type Culture Collection). These cells were cultured in RPMI-1640 (Nissui, Tokyo, Japan) or DMEM medium (Nikken Bio Medical Laboratory, Kyoto, Japan), supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum at 37˚C in 5% CO 2 .
A total of 55 samples of CRC tissues together with adjacent non-neoplastic mucosa were obtained from patients who underwent surgery at the Department of Surgery and Clinical Oncology, Osaka University, between 2000 and 2001. The age of the patients ranged from 28 to 81 years (mean age: 61 years). The resected surgical specimens were fixed in 10% buffered formalin, dehydrated in graded ethanol, and embedded in paraffin. Tissue sample of sufficient quantity was frozen immediately in liquid nitrogen and stored at -80˚C until use for reverse transcription-polymerase chain reaction (RT-PCR), methylation assay or immunoblotting. Samples of non-neoplastic mucosa were excised at least 5 cm lateral to the tumor. The study protocol was approved by the Human Ethics Review Committee of Osaka University, Graduate School of Medicine.
Immunostaining. The tissue specimens fixed in 10% buffered formalin were sliced into 4-µm thick sections, deparaffinized in xylene and rehydrated with graded concentrations of ethanol. Immunostaining was performed using the Vectastain ABC peroxidase kit (Vector Laboratories, Burlingame, CA) after boiling for antigen retrieval, as described in our previous studies (28, 29) . Anti-p16 INK4 polyclonal antibody, which was raised against a full-length recombinant GST-p16 fusion protein, was purchased from PharMingen (San Diego, CA). The primary antibody was applied to the sections at a dilution of 1:400. The human breast epithelial cell line HBL100, which expresses a high level of p16, and the glioblastoma cell line T98G in which the p16 gene is inactivated by homozygous deletion, were used as positive and negative controls, respectively (30) . For the absorption test, the immunogen was obtained from PharMingen.
Evaluation of immunohistochemistry.
Inflammatory cells served as positive internal controls and nuclear staining for p16 was considered positive as reported previously (30) (31) (32) . Ten fields in each specimen were randomly selected and examined under high power magnification and >500 cells were counted in order to determine the labeling index (LI), which represented the percentage of cells that were p16-positive. The samples were then classified into three groups according to the value of LI: group A consisted of tissue samples that contained >50% p16-positive cells, group B contained 10-50% p16-positive cells, and group C contained <10% p16-positive cells. Staining was repeated at least twice to eliminate possible technical errors, and the results were reproducible.
Western blot analysis. Approximately 5x10
6 cells or 100 mg of tissue were homogenized and lysed in 1.0 ml of lysis buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP40, 1 mM PMSF, 10 µg/ml aprotinin and 10 µg/ml leupeptin, and then placed on ice for 10 min. The lysates were clarified by centrifugation at 15,000 x g for 25 min at 4˚C. The protein samples were subjected to SDS-PAGE (15% gels) and immunoblotting was performed as described in our previous studies (28) (29) (30) . The final dilution of the primary antibody was 1:1,000.
RNA extraction and RT-PCR analysis.
Total RNA was extracted with a single-step method using TRIzol reagent (Invitrogen Corp., Carlsbad, CA), and cDNA was generated using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI). Semi-quantitative analysis for expression of p16 mRNA was performed by the multiplex RT-PCR technique, using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as the internal standard (33, 34) . To minimize the inter-PCR difference, PCR was performed with GAPDH and p16 primers in identical tubes under unsaturated conditions, as described in our previous studies (33, 35, 36) . PCR reactions were performed in a total volume of 25 µl of reaction mixture containing 2 µl of cDNA template, 1X Universal PCR buffer, 2 mM deoxynucleotide triphosphates, 20 pmol of primer for p16, 4 pmol of each primer for GAPDH, and 1 unit of Taq DNA Polymerase (AmpliTaq Gold; Roche Molecular Systems, Inc., Alameda, CA). The primer set for p16 was designed to be localized in exon 1 and exon 2 of the p16 gene, flanking intron 1 and tested to ensure amplification of cDNA only, so that amplification of potentially contaminating genomic DNA could be avoided. The sequences of these PCR primers were as follows: p16 sense primer, 5'-AGC CTT CGG CTG ACT GGC TGG-3'; p16 antisense primer, 5'-CTG CCC ATC ATC ATG ACC TGG A-3'. The primers for GAPDH were synthesized as described previously (34) . The sizes of the amplicons for p16, and GAPDH were 139 and 181 bp, respectively. The PCR conditions were as follows: a) initial denaturing at 95˚C for 12 min; b) 35 cycles of 94˚C for 1 min, 56˚C for 1 min, and 72˚C for 1 min; and c) a final extension at 72˚C for 10 min. Each PCR product (10 µl) was electrophoresed on 2% agarose gels and stained with ethidium bromide. The PCR products were assayed by densitometry.
Methylation-specific PCR (MSP).
To detect methylation at the 5' CpG island in the p16 promoter region, MSP was performed using the CpGenome DNA Modification kit (Chemicon International, Inc., Temecula, CA), as recommended by the supplier (30) . Briefly, genomic DNA was modified by treatment with sodium bisulfite, which converts all unmethylated cytosines to uracils while 5-methylcytosines remain unaltered. PCR amplification was then carried out using primers specific for either methylated or unmethylated DNA (CpG WIZ Amplification Kit, Chemicon International, Inc.). The PCR mixture contained Gene-Amp 10X Universal PCR buffer, 2.5 µl of 2.5 mM dNTPs, 1.0 µl of primer pairs, 2 µl of template DNA, and 0.2 µl of AmpliTaq Gold (Roche Molecular Systems, Inc., Alameda, CA) for a final volume of 25 µl. Amplification was performed in a temperature cycler (Takara, Shiga, Japan) for 35 cycles (45 sec at 95˚C, then at annealing temperature for 45 sec, and finally 60 sec at 72˚C), followed by a final 5-min extension at 72˚C. The PCR samples were loaded onto a 2% agarose gel, stained with ethidium bromide, and directly visualized under UV illumination.
Quantitative real-time MSP using LightCycler. Quantitative PCR was performed using LightCycler system (Idaho Technology Inc., Salt Lake City, UT), as described in our previous studies (36, 37) . Briefly, 10 µl PCR reaction contained 0.2 µM of each primer, LightCycler-DNA Master SYBR Green I (Roche Molecular Systems, Inc.), 4 mM MgCl 2 and 2 µl of template DNA. PCR conditions were set up as follows: one cycle of denaturing at 95˚C for 2 min, followed by 50 cycles of 95˚C for 0.1 sec, 62˚C for 5 sec and 72˚C for 18 sec. Fluorescence was acquired at the end of each 72˚C extension phase. The melting curves of the final PCR products were analyzed after 50 cycles of PCR amplification by cooling samples to 65˚C, increasing the temperature up to 99˚C at a rate of 0.1˚C/sec, and monitoring fluorescence at each 0.1˚C. Quantification data from each sample were analyzed using LightCycler analysis software. Two real-time quantitative PCR reactions were performed for the detection and quantitation of the bisulfite-unconverted methylated version of the p16 gene and the bisulfite-converted unmethylated version of the p16 gene. Serial dilutions of methylated or unmethylated control genomic DNAs (CpG WIZ Amplification kit, Chemicon International, Inc.) were used for constructing the standard curves (Fig. 1) .
The methylation index (MI) in each sample was calculated using the following equation (38) , MSP was performed using 10-fold serial dilutions of methylation control genomic DNA from 2 ng to 2 µg. The PCR products were monitored by the fluorescence of dsDNA-specific dye SYBR Green I. (B), Based on the amplification results of (A), a standard curve was drawn using LightCycler software. Similar curves were drawn for unmethylated p16 DNA products, using bisulfite-converted unmethylated control genomic DNA (data not shown).
Statistical analysis. Contingency tables were used to determine correlations between the expression of p16 protein and clinicopathologic parameters. Statistical association was determined by Fisher's exact test and mean values were compared by the Mann-Whitney U test using the Statview J-5.0 program (SAS Institute Inc., Cary, NC).
Results
Methylation and p16 gene expression in cell lines. Seven cell lines were examined for the presence of methylation in the p16 promoter region using MSP. The breast cancer cell line MDAMB468, which retains only the unmethylated p16 gene, was used as a negative control, while the SW480 CRC cell line served as a positive control for hypermethylation of the p16 gene, as described previously (30) . The HBL100 breast epithelial cell line and the MDAMB468 cell line displayed a band only when amplified with primers for unmethylated DNA ( Fig. 2A, lanes 1 and 2) . By contrast, like the SW480 cell line, the CRC cell lines, LoVo, HT29 and DLD1 displayed a clear band of methylated DNA but not unmethylated DNA ( Fig. 2A, lanes 4-7) . The HCT116 cell line alone displayed bands of both methylated DNA and unmethylated DNA ( Fig. 2A, lane 3) . The MDAMB468 and the HBL100 cell lines expressed an intense band for p16 mRNA (Fig. 2B, lanes 1 and 2) , but CRC cell lines SW480, LoVo, HT29, and DLD1 did not express p16 mRNA (Fig. 2B, lanes 4-7) . In HCT116 cells, a modest band for p16 mRNA was detected (Fig. 2B, lane 3) .
Methylation and p16 gene expression in surgical specimens. Twenty-one paired normal and cancer tissues were then examined for the presence of p16 gene methylation using MSP. All surgical specimens displayed a band of unmethylated DNA that could be derived from unmethylated DNA of normal colonic cells and cancer cells as well as normal constituents in the stroma such as vascular endothelial cells, smooth muscles, fibroblasts, and inflammatory cells (Fig. 3A) . A band of methylated DNA was found in 2 normal mucosa samples (9.5%) and 9 (42.9%) cancer tissues.
To confirm the conversion efficiency of bisulfite from unmethylated cytosines to uracils, a mixing experiment was performed. Prior to bisulfite treatment, a cancer DNA sample displaying both methylated and unmethylated bands was diluted serially with increasing amounts of unmethylated DNA from HBL100 cells. As expected, methylated band gradually decreased, resulting in an increasing ratio of unmethylated to methylated product in the mixture (Fig. 4) . KIM 3 and 5) . On the other hand, p16 mRNA was detected in 10 of 12 methylation-minus CRC tissues (lane 2) and 5 of 9 methylation-plus CRC tissues (lane 6). GAPDH served as an internal control in duplex PCR. N, normal mucosa; T, CRC tumor tissue. p16 mRNA was undetectable in 12 of 21 normal mucosa samples (57.1%) (Fig. 3B, lanes 1, 3 and 5 ). p16 expression was detected in 9 normal mucosa samples, all of which were devoid of p16 methylation; the expression level was generally weak (intensity ratio of p16 band to GAPDH band <0.5). On the other hand, p16 mRNA was detected in 11 of 12 methylation-negative CRC tissues (Fig. 3B, lane 2) and 6 of 9 methylation-positive CRC tissues (Fig. 3B, lane 6) . Strong p16 mRNA expression (intensity ratio ≥0.5) was detected in 7 CRC tissues only in the methylation-negative group (results summarized in Fig. 5 ). When expression of p16 mRNA was compared between paired normal mucosa and tumor samples, only 1 of 21 cases (4.7%) showed a decrease in p16 mRNA expression during carcinogenesis (from normal mucosa to cancer tissue).
Methylation-specific real-time PCR.
We then measured the extent of p16 methylation in methylation-positive CRC tissues (n=9) by a methylation-specific real-time PCR method. The MI varied widely as follows: 0.28, 0.29, 0.30, 0.32, 0.45, 0.66, 0.78, 0.79, and 0.91. The MI values were then compared with p16 mRNA expression (Fig. 6A) and plotted (Fig. 6B) . CRC tissues with high methylation had relatively low p16 was diluted serially (every 5-fold, lanes 2-4) with increasing amounts of unmethylated DNA from HBL100 cells. Then, PCR was performed. Unmethylated DNA remained unchanged, while methylated DNA product decreased in the mixture, enduring high conversion efficiency of bisfulfite from unmethylated cytosines to uracils. U, unmethylated DNA; M, methylated DNA. Figure 5 . p16 mRNA expression stratified by the presence of methylation in non-neoplastic tissue (A) and cancer tissue (B). When high expression of p16 mRNA was defined as an intensity ratio of the p16 mRNA band to the GAPDH mRNA band of ≥0.5, 7 CRC tissues without methylation belonged to this category (solid circles). There were no high expressors of p16 in nonneoplastic tissues. Nine normal tissues devoid of methylation expressed weak p16 mRNA expression (intensity ratio of p16 mRNA band to GAPDH mRNA band <0.5, grey circles). Open circles indicate samples that did not express p16. expression. When CRC cases were classified into three categories according to MI; no-methylation (MI = 0), lowmethylation (0< MI <0.5), high-methylation (MI ≥0.5), there was a significant difference in p16 mRNA expression between the high-methylation group and the no-methylation group or low-methylation group (p=0.012, p=0.037, respectively, Fig. 6C ).
Expression of p16
INK4 protein in surgical specimens. Western blotting of 8 pairs of the non-neoplastic colonic mucosa and their corresponding CRC tissues showed that the intensity of the p16 band was scarcely detected in the non-neoplastic mucosa and an increased level of p16 expression was noted to various extent in cancer tissues (Fig. 7) . RT-PCR indicated that p16 mRNA expression correlated well with p16 protein expression (Fig. 7) . Immunostaining of the corresponding tissue samples showed that p16 quantity determined by Western blot was correlated with p16 protein expression in cancer tissues, but not in stromal cells (Fig. 8) . The non-immune rabbit serum and antibodies with preabsorbed immunogen yielded no staining in the samples and the HBL100 cells displayed a positive staining and the T98G cells had no staining (data not shown).
In total, 55 paired samples were immunohistochemically stained with the anti-p16 antibody. In the normal colonic mucosa, clear nuclear p16 was detected only occasionally and the LI was <5% in all 55 cases tested (data not shown). In contrast, p16 was abundantly expressed in the majority of CRC tissues, and was localized in the nuclei and cytoplasm. When CRC cases were classified into three groups according to their LI, 10 cases (19%) were classified into group A (LI >50%), 43 (77%) into group B (LI 10-50%) and 2 (4%) into group C (LI <10%). In at least 53 cases (96%), overexpression of p16 was noted in CRC tissue when compared to the corresponding non-neoplastic mucosa. In the 21 CRC tissues utilized for methylation assay, the results of p16 staining correlated well with p16 mRNA expression (data not shown).
Relationship between p16
INK4 expression and clinicopathologic parameters. The relationship between the level of staining of p16 in CRC samples and several clinicopathologic parameters was examined. These parameters included gender, tumor site, disease stage, histological grade, lymph node metastasis, depth of invasion, distant metastasis, age and size (Table I) . High p16 expression level was associated with a low incidence of lymph node metastasis (group A vs. group B and C, p=0.003), and p16 expression was associated with small tumor size (p=0.048). There was no correlation between p16 expression and other clinicopathologic parameters.
Discussion
Dysregulation of CKIs, negative regulators of the cell cycle, is often found in human malignancies. The expression of p21
Waf1 is reduced in aberrant crypt foci with dysplasia and carcinomas of the colon and its high expression is related to a better prognosis in gastric cancer (39) (40) (41) . A decrease in p27 Kip1 is associated with poor prognosis or high grade tumors in various types of human cancer (29, 42) . Loss or decreased expression of p16 is found in a subset of primary cancers (8) (9) (10) (11) (12) . These lines of evidence indicate that inactivation of CKI may play a role in carcinogenesis and/or tumor progression of various types of human cancers. However, it appears to be unlikely that loss of p16 plays a central role in tumorigenesis of the colorectum in vivo. In this study we found that p16 gene expression was often upregulated in primary CRC tissues compared with non-neoplastic mucosa at both the mRNA and protein levels, though p16 mRNA was lost in most CRC cell lines. These findings are consistent with previous reports (15, 24, 25) and suggest that the regulatory mechanism of p16 gene expression may be quite distinct between cell lines and in vivo tissues of the colorectum.
Loss of p16 mRNA in CRC cell lines is understandable since a band corresponding to the methylated p16 gene was generally present in all CRC cell lines, and hypermethylation, as well as gene alterations, is known to be a major mechanism for inactivation of p16 gene transcription (13, 14) . On the other hand, a methylated p16 band was detected in 42.9% (9/21) of surgically resected CRC tissues, consistent with other reports that p16 methylation is present in 29-55% of CRC tissues (18) (19) (20) (21) (22) . However, unlike cell lines, such methylation-positive CRC tissues frequently still expressed p16 mRNA. One clue to explain the differential regulatory mechanisms between CRC cell lines and CRC tissues may be methylation density in the p16 promoter region, rather than the presence of methylation per se (26, 27) . In support of this hypothesis on regulation of the p16 transcript, even cell lines exhibited varying extent of p16 methylation, which could affect p16 gene expression (38, 43) . We also confirmed that the HCT116 cell line whose one allele of p16 is methylated and silenced and the other is mutated and unmethylated (44) , did display both a methylated and an unmethylated p16 band, leading to only modest expression of p16 mRNA (Fig. 2) . Other CRC cell lines displaying only the methylated p16 band (MI: 100%) exhibited no p16 mRNA expression. Although methylation density of the p16 gene has been measured in several tumor cell lines, the extent of methylation in CRC tissues has yet not been clarified. Table I . Relationship between p16 expression and clinicopathologic parameters in colorectal cancer. -
We performed quantitative MSP, using CRC tissues that exhibited p16 gene methylation. Our findings showed that there was a significant decrease in p16 mRNA level in the high-methylation group compared to the no-methylation or low-methylation groups (Fig. 6C) . These findings suggest that a hyper-methylation density would facilitate transcriptional repression of the p16 gene in CRC tissues, but that lowmethylation may only partially repress p16 gene expression. It was of interest that MI was variable (range: 0.28-0.91) and this could be a characteristic of in vivo p16 gene methylation. Concordant p16 expression at protein and RNA level (Fig. 7) suggest that p16 expression may be regulated at transcriptional level. Immunohistochemistry revealed that low level of the p16 protein represented reduced expression within neoplastic epithelium, but not in stromal cells (Fig. 8) . In the nomethylation group, CRC tissues exhibited a wide range of p16 mRNA levels (Fig. 6C) . This suggests that the basal p16 mRNA level could be also variable in the methylationpositive group, and therefore p16 expression level may not be determined by methylation extent alone. This might account for a few exceptional CRC samples that expressed some p16 mRNA even with the highest MI (0.91) or displayed relatively low p16 mRNA expression despite a low MI (0.29, 0.3) (Fig. 6B) .
It remains controversial whether p16 expression is predictive of clinical events. Inactivation of the p16 gene is associated with aggressive disease phenotype including lymph node metastasis, shorter survival in esophageal cancer and advanced stage of hepatocellular carcinomas (45, 46) . Conversely, it has been reported that high levels of p16 are associated with poor prognosis in carcinomas of the ovary, prostate, and breast (47) (48) (49) . In the latter tumor types, increased p16 expression might in turn reflect upregulated activity of the cell cycle positive regulators. Our immunohistochemical analysis showed that low p16 expression in CRC tissues correlated with larger tumor size and lymph node metastasis. Other investigators have also shown that p16 expression in CRC tissues was associated with low proliferative activity (24, 25) and hypermethylation of the p16 gene was associated with advanced tumor stage and shorter survival (20, 22) . Taken together, these findings suggest that p16, despite its upregulation, may act as a tumor suppressor gene in CRC tissues, and it is likely that methylation would at least in part contribute to reduction in p16 expression, resulting in facilitation of tumor expansion and enlargement of CRC.
Overexpression of the p16 tumor suppressor gene in CRC tissues appeared to be paradoxical and we are not yet certain of the reason for this. However, overexpression of p16 is not limited to CRC, but is also seen in other gastrointestinal tumors, such as gastric and intestinal cancers (24, 25, 30, 50) . Moreover, studies have shown that several human cancers display increased expression of negative cell cycle regulators, although no mutations of the p27
Kip1 and p21 Waf1 genes have been reported for human cancer tissues. High levels of p21
Waf1 expression are seen in glial tumors, non-small cell lung cancer, and breast cancer (51) (52) (53) . p27
Kip1 expression is increased in a subset of cancers, including breast and colon cancers (29, 54 ). The precise reason for why negative regulators of the cell cycle often display increased expression is unknown at present. One explanation proposed by Weinstein is that multistage carcinogenesis is not simply a summation of the individual effects of oncogene activation and tumor suppressor gene inactivation, but that the evolving cancer cell must maintain a state of homeostasis between positive-and negative-acting factors in order to maintain structural integrity, viability, and normal replication (55) . In this context, we speculate that p16 gene methylation may break the homeostatic balance, thereby tipping the balance towards positive regulators.
In conclusion, our study demonstrated that CRC tissues exhibited a variable methylation density of the CpG island in the p16 gene promoter, suggesting that p16 expression may be repressed in a methylation-dependent manner. Our data suggest that the majority of CRC tissues overexpressed p16 protein, and that low p16 expression among CRC tissues, probably via hypermethylation, may contribute to tumor enlargement and lymph node metastasis.
